Postoperative Analgesia
Conditions
Keywords
erector spinae plane block, magnesium sulphate, ketamine HCl, bupivacaine, analgesia
Brief summary
In this study, it will aimed to evaluate the effect of magnesium sulfate and ketamine HCl added to local anesthetic on postoperative pain management in the ultrasound-guided erector spina plane (ESP) block in patients will undergo video-assisted thoracoscopic surgery.
Detailed description
Patients who will undergo lung resection with elective video-assisted thoracoscopic surgery will be included in the study. After routine monitoring, general anesthesia induction, and intubation with a double-lumen tube, patients who are placed in a lateral position will receive an ESP block at the T5 level, accompanied by ultrasonography, for postoperative analgesia. For this purpose; Group I (control group) 0.5% bupivacaine 20 ml, Group II 0.5% bupivacaine 20 ml+150 mg MgSO4, Group III 0% ,5 bupivacaine 20 ml+2 mg/kg ketamine HCl will be administered. In all groups, the total volume will completed to 25 ml with 0.9% NaCl. After surgery, hemodynamic values (heart rate, systolic and diastolic blood pressure), oxygen saturation, VAS scores (at rest and effort), Ramsey sedation score, patients satisfaction scores, PCA morphine consumption, additional analgesic requirements, and side effects will be recorded.
Interventions
DRUGBupivacain
Bupivacaine is a local anesthetic agent commonly used in ESP block.
DRUGMagnesium sulfate
Magnesium is an adjuvant agent that can be added to the local anesthetic agent to increase analgesic effectiveness..
DRUGKetamine Hydrochloride
Ketamine Hydrochloride is an also adjuvant agent that can be added to the local anesthetic to increase analgesic effectiveness.
Sponsors
Cukurova University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* lung resection with video-assisted thoracoscopy, * voluntarily agree to participate in the study, * over 18 years old, * ASA I-III
Exclusion criteria
* ASA\>III * Coagulation disorders or anticoagulant agent therapy, * Allergy or hypersensitivity to any drug to be will be used in the study, * Epilepsy, * High intracranial pressure, * Unwillingness to participate in the study * Inability to use the PCA device
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pain scores | Change from baseline pain scores at 24 hours | postoperative pain scores will recorded used Visual Analog Scale (VAS, 0= no pain, 10=worst pain) |
| morphine consumption | Change from baseline morphine consumption at 24 hours | At the end of the surgery, patients will allowed to use the patient controlled analgesia (PCA) device. The PCA will deliver bolus doses of morphine (0,02 mg/kg) every 10 minutes without a background infusion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| side effects | postoperative 24 hours | All of patients will visited in the thoracic surgery ward after surgery and side effects (if occured) will recorded. |
Countries
Turkey (Türkiye)
Outcome results
None listed